How to Help Your Patients Find Yupelri in Stock: A Provider's Guide

Prescribing Yupelri (revefenacin) is often the easy part. Getting patients to actually fill and consistently use their prescription is where the challenges arise. Because Yupelri is a specialty nebulized COPD medication not routinely stocked at most retail pharmacies, providers who prescribe it frequently encounter patient calls about access difficulties, delays, and confusion. This guide offers practical workflows to reduce those barriers.

The Core Problem: Retail Pharmacies Don't Reliably Stock Yupelri

Yupelri (revefenacin) is a niche specialty product with a list price of $1,655.34 per 30-day supply and no generic equivalent. Most community retail pharmacies — including many large chains — do not keep it in regular stock because it's dispensed infrequently and ties up significant inventory capital.

When you send a Yupelri prescription to a standard retail pharmacy, your patient may be turned away and told to try elsewhere — often without a clear recommendation of where to go. This experience leads to medication delays, therapy gaps, and patient frustration that can undermine adherence.

Step 1: Route Prescriptions to Specialty Pharmacies

The single highest-impact change you can make is to route Yupelri prescriptions directly to specialty pharmacies rather than standard retail locations. Specialty pharmacies that focus on respiratory or complex chronic disease medications regularly stock Yupelri and have established prior authorization workflows.

Consider identifying 1–2 preferred specialty pharmacy partners in your area and establishing a direct referral workflow. Many specialty pharmacies will work directly with your office staff to handle the prior authorization and insurance verification before the patient even leaves the appointment.

Step 2: Submit Prior Authorization Documentation Proactively

Most major payers require prior authorization for Yupelri. UnitedHealthcare's 2026 criteria (effective February 15, 2026) require documented moderate-to-severe COPD plus one of the following:

History of failure, contraindication, or intolerance to Spiriva HandiHaler or Respimat (tiotropium); OR

Documented inability to use handheld MDI/DPI/SMI devices due to physical or cognitive impairment

To minimize delays, submit the prior authorization request at the time of prescribing rather than waiting for the pharmacy to trigger it. Include specific clinical language about the patient's inhaler ability or prior medication history. If the prior authorization is denied on first submission, check for missing documentation before escalating to peer-to-peer review.

Step 3: Recommend Mail-Order for Ongoing Therapy

For patients on long-term Yupelri therapy, mail-order through their insurance plan's pharmacy benefit manager is often the most reliable dispensing option. Express Scripts, CVS Caremark, and Optum Rx all cover Yupelri and can provide 90-day supplies delivered to the patient's home.

A 90-day supply eliminates the monthly stress of finding a stocked pharmacy, reduces copay per dose in many plans, and improves adherence by ensuring medication is always on hand. Counsel patients to maintain at least a 2-week supply buffer so they have time to reorder before running out.

Step 4: Address Medicare Part B Billing Correctly

For Medicare patients, Yupelri is typically covered under Medicare Part B (not Part D) as a nebulizer solution administered as durable medical equipment (DME). The HCPCS J-code for Yupelri is J7677 (revefenacin inhalation solution, FDA-approved, 1 microgram). Medicare covers 80% of the allowable cost; patients are responsible for the 20% coinsurance.

Patients with Medigap supplemental insurance may pay as little as $0 out of pocket. Patients without supplemental insurance face a 20% copay on a medication with a WAC above $1,600/month — an important counseling point. Be aware that the Viatris manufacturer savings card is not valid for Medicare patients.

Step 5: Counsel Commercially Insured Patients About the Savings Card

Commercially insured patients who are not enrolled in any government healthcare program may be eligible for the Yupelri Savings Card from Viatris. Eligible patients may pay as little as $0 per monthly fill for up to 12 fills per calendar year. The program is not available to Medicare, Medicaid, or TRICARE beneficiaries.

Patients can enroll at activatethecard.com/yupelri. Consider adding information about this program to your patient education materials for Yupelri prescriptions.

Step 6: Know When to Use the Viatris Patient Assistance Program

For patients who are uninsured or underinsured and do not qualify for the savings card, the Viatris Patient Assistance Program (Group One Medicines) provides Yupelri at no cost to eligible patients. Eligibility is based on financial criteria. To apply, contact Viatris at 800-796-9526 or ViatrisPAP@viatris.com. Applications can be faxed to 877-427-7290.

Step 7: Use medfinder When Patients Report Difficulty Finding Stock

When patients call your office reporting that they cannot find Yupelri in stock, directing them to medfinder.com can save significant staff time and patient frustration. medfinder is a paid service that calls local pharmacies on the patient's behalf to check stock, and texts results directly to the patient. This eliminates the office staff from acting as a pharmacy locator while giving patients an actionable solution. For more background on Yupelri availability, see: Yupelri Availability: What Providers Need to Know in 2026.

Practice Checklist: Yupelri Access Workflow

Identify 1–2 preferred specialty pharmacy partners for Yupelri prescriptions

Submit prior authorization at time of prescribing with explicit documentation of inhaler inability or tiotropium failure

Counsel long-term patients to use mail-order for a 90-day supply

Verify Medicare vs commercial insurance to select the appropriate savings approach (Medicare Part B billing vs. Savings Card)

Provide patients with medfinder.com as a resource when they report difficulty finding stock

Track prior authorization expiration dates — reauthorize proactively to prevent therapy gaps